Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Viagenpumatucel-L - NightHawk Biosciences/University of Miami

Next Previous
Drug Profile

Viagenpumatucel-L - NightHawk Biosciences/University of Miami

Alternative Names: Ad100-gp96Ig-HLA A1; Gp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell line; gp96-Ig lung cancer vaccine - NightHawk Biosciences /University of Miami; HS-110; HS-L1

Latest Information Update: 08 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Miami
  • Developer NightHawk Biosciences
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Heat-shock protein stimulants; Immunostimulants; OX40 ligand stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 31 Mar 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, In adults) in USA (Intradermal) (before March 2023)
  • 31 Mar 2023 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (before March 2023)
  • 01 Jan 2023 NightHawk Biosciences terminates its licensing agreement with University of Miami for gp96 and TNFRSF25 platforms

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top